重组霍乱毒素B亚基与恶性疟原虫多抗原表位融合蛋白对恒河猴的免疫保护作用研究

使用重组霍乱毒素B亚基（CTB）与恶性疟原虫抗原表位融合蛋白（AWTE）免疫恒河猴,研究其免疫应答并观察对食蟹疟原虫攻击的保护作用。结果表明：在0,14,28天分别通过鼻腔和肌肉注射免疫恒河猴,第3次免疫后2周,抗CTB抗体平均滴度可达1∶512（鼻腔免疫）和1∶10000（肌肉免疫）;肌肉免疫后抗疟原虫抗体滴度也显著高于鼻腔免疫组。用125×10⁸个食蟹疟子孢子攻击,对照组5只恒河猴在攻击后10～14d全部感染,其中1只在攻击后21d死亡,另4只重度感染,感染持续30d以上。鼻腔免疫组的5只动物均在攻击20d后出现原虫,其中3只轻度感染,感染持续4d后即恢复,其余2只感染持续36d以上。肌肉注射组3只未受感染,其余2只在攻击后19d后轻度感染,感染4d后即完全恢复。以上结果表明,使用霍乱毒素B亚基为载体蛋白构建的重组疟疾疫苗具有良好的免疫原性,对食蟹疟攻击具有良好的交叉免疫保护作用。     

猪霍乱沙门菌载体介导猪瘟病毒DNA免疫研究

构建了猪瘟病毒(CSFV)主要保护性抗原E2基因的真核表达质粒pVAXE2。将其电转化猪霍乱沙门氏菌C500疫苗株,得到了携带pVAXE2质粒的猪霍乱沙门氏菌工程菌株S.C500/pVAXE2,对该菌株的特征、培养特性和生化特性进行了鉴定。分别用1×10⁸CFU、2×10⁹CFU S.C500/pVAXE2经口服或肌肉注射免疫小鼠和家兔,间接ELISA检测免疫动物的特异性抗体,在第三次免疫后2周用20ID50猪瘟兔化弱毒和致死量猪霍乱沙门氏菌强毒株对免疫兔进行攻击。结果表明,S.C500/pVAXE2保持了猪霍乱沙门氏菌原有形态特征、培养特性和生化特性,免疫鼠和兔都产生了抗CSFV和猪霍乱沙门菌的ELISA抗体,免疫家兔能抵抗猪瘟兔化弱毒株和猪霍乱沙门氏菌强毒株的攻击。显示了以S.C500为DNA运输载体构建二联或多联猪用疫苗的可行性。     

牛种布鲁氏菌2308不同途径小鼠感染模型的建立与评估

[背景] 布鲁氏菌可经口、皮肤、黏膜和呼吸道感染人和动物。小鼠是布鲁氏菌研究中最常用的模型动物。[目的] 建立牛种布鲁氏菌2308不同途径和剂量感染BALB/c小鼠的模型,为布鲁氏菌小鼠感染试验提供参考。[方法] 用10¹-10⁵ CFU这5个不同感染剂量,分别经注射、口服和点眼方式感染BALB/c小鼠。在感染后不同时间点采集小鼠血清,检测IgG、IgM、IgA抗体含量、脾脏重量及脾脏含菌量,评价布鲁氏菌经不同途径感染BALB/c小鼠的效果。[结果] 10 CFU是注射感染BALB/c小鼠的最小感染剂量;10⁵ CFU是口服感染BALB/c小鼠的最小感染剂量。10¹-10⁵ CFU这5个不同感染剂量经点眼途径均未能成功感染BALB/c小鼠。在10⁵ CFU感染剂量下,口服与注射感染组小鼠每克脾脏平均含菌量分别为10^5.673 CFU/g和10^5.009 CFU/g,无显著差异（P>0.05）,但口服感染组小鼠脾脏平均重量为0.310 g,显著高于注射感染组0.165 g （P<0.01）。在试验期内,注射感染组和口服感染组小鼠体内IgG抗体的滴度均随感染时间延长而持续升高;整体上,口服感染组IgG抗体峰值显著高于注射感染组;2组IgM抗体变化趋势一致;口服感染组有2只小鼠在感染28 d后产生IgA抗体,注射感染组均未检测到IgA抗体。[结论] 建立了牛种布鲁氏菌2308通过不同途径感染BALB/c小鼠的模型。     

抗鼠疫耶尔森菌F1抗原单克隆抗体对小鼠的被动免疫保护作用

目的研究抗鼠疫耶尔森菌F1抗原单克隆抗体(单抗)被动免疫BALB/c小鼠后的抗鼠疫保护效果,确认鼠疫抗体治疗依据,探索鼠疫免疫学治疗的评价手段。方法将BALB/c小鼠随机分组,用不同剂量的抗鼠疫耶尔森菌F1抗原单抗4C6和2D2分别进行免疫,再分别用不同剂量的鼠疫强毒菌攻击,通过小鼠的存活率和存活时间,判定F1单抗免疫小鼠被动保护其抵抗鼠疫强毒菌攻击的有效性和剂量相关性。结果在14 d的观察期内,在100.0 MLD鼠疫强毒菌攻击下,4C6单抗400.0μg组、200.0μg组、100.0μg组、50.0μg组和25.0μg组小鼠的存活率分别为100%、83%、50%、50%和0%,平均存活时间分别为15.00 d、14.67 d、13.00 d、13.50 d和9.67 d;2D2单抗400.0μg组、200.0μg组、100.0μg组、50.0μg组、25.0μg组小鼠的存活率分别为83%、50%、50%、33%和0%,平均存活时间分别为14.83 d、13.33 d、12.67 d、12.33 d和8.00 d。在10.0 MLD鼠疫强毒菌攻击下,4C6单抗50.0μg组、25.0μg组和12.5μg组小鼠的存活率分别为83%、83%和17%,平均存活时间分别为14.17 d、14.50 d、9.83 d;2D2单抗50.0μg组、25.0μg组、12.5μg组小鼠的存活率分别为100%、33%和33%,平均存活时间分别为15.00 d、12.33d和11.67 d。2.0 MLD和1.0 MLD攻击的未免疫对照组小鼠全部死亡,平均存活时间分别为6.1 d和6.7 d。F1抗原单抗的免疫剂量与小鼠的平均存活时间和存活率有比较明显的相关性(P<0.05)。结论用抗鼠疫耶尔森菌F1抗原单抗被动免疫小鼠,在受到鼠疫强毒菌攻击时,对小鼠具有免疫保护作用。     

抗禽流感病毒多表位DNA疫苗的构建及其免疫效力研究

多表位DNA疫苗是建立在常规DNA疫苗基础上的一种新型疫苗。它是用表位作免疫原,这样就比较容易在一个表达载体上克隆病原体的多个抗原基因中具有免疫活性的部分。本试验以H5N1亚型禽流感病毒的HA和NP基因及其表位为基础构建了4个重组质粒：1 pIRES/HA（表达全长的HA基因）;2 pIRES/tHA（只表达HA基因的主要抗原表位区）;3 pIRES/tHANpep（融合表达HA基因的抗原表位区和NP基因的3个CTL表位）;4 pIRES/tHANpep-IFN-γ（用鸡的IFN-γ基因取代质粒pIRES/tHANpep中的neo基因）。分别用这4个重组质粒和空载体质粒pIRES1neo肌注免疫30日龄SPF鸡。免疫3次,间隔为2周,每次每只鸡的剂量为200μg。第3次免疫后两周以高致病性禽流感病毒H5N1强毒攻击,免疫及攻毒前后均采血检测HI抗体效价和外周血CD4⁺、CD8⁺T细胞的变化。结果发现,攻毒前各质粒免疫组均检测不到HI抗体,攻毒后1周存活鸡HI抗体效价迅速升高到64～256。流式细胞仪检测显示外周血CD4⁺、CD8⁺T细胞在疫苗免疫后都有不同程度的升高。空载体质粒对照组鸡（10只）在攻毒后3～8 d内全部死亡,其他各重组质粒免疫组鸡都获得了部分保护,保护率分别是：pIRES/HA组为545%（6/11）,pIRES/tHA组为30%（3/10）,pIRES/tHANPep组为36.3%（4/11）, pIRES/tHANPepIFNγ组为50%（5/10）。这些结果表明我们构建的多表位DNA疫苗能够诱导机体产生特异性免疫应答,并在同型禽流感强毒攻击时对鸡只提供了一定的保护。     

多肽免疫抑制牙龈卟啉单胞菌引起的小鼠感染及牙槽骨吸收作用的研究

目的探讨牙龈卟啉单胞菌(Porphyromonasgingivalis,P.g)血凝素2(hemagglutinin-2,HA-2)的氯化血红素结合位点多肽作为抗原免疫小鼠,对降低P.g感染后毒性和抑制牙周炎牙槽骨吸收的作用。方法将多肽与牛血清白蛋白(Bovine serum albumin,BSA)偶联作为抗原免疫BALB/c小鼠。P.g国际标准菌株ATCC33277厌氧培养,皮下注射菌液,监测小鼠脓肿的大小及转归,评价多肽对P.g皮下感染的保护作用;口腔接种细菌感染小鼠,检测小鼠牙周炎牙槽骨吸收量,评价其对于P.g引起的牙周炎牙槽骨吸收的保护作用。结果多肽DGFPGDHYAVMISK作为抗原免疫小鼠可减小小鼠皮下接种P.g处形成脓肿的大小,并加快皮下脓肿的愈合;可抑制口腔感染P.g后小鼠牙周炎模型牙槽骨的吸收。结论多肽DGFPGDHYAVMISK免疫小鼠对P.g感染小鼠具有一定的保护作用;可减少小鼠牙周炎模型牙槽骨的吸收。为开发新的牙周病防治方法奠定基础。     

小鼠胸腺髓质上皮细胞系体内诱导胸腺细胞功能成熟

来源于BALB/c小鼠 (H-2^d)胸腺的髓质上皮细胞系MTEC1细胞表达H-2^d和I -A^d 分子 .为研究上皮细胞诱导胸腺细胞阳性选择及功能分化的能力 ,首先用γ 线照射C5 7BL/6J小鼠(H-2^d) ,再经静脉注射 (H-2^b×d)F1代骨髓细胞 ,制备 H-2^b×d→H-2^b)嵌合体 ,然后将MTEC1细胞注射到嵌合体胸腺内 .注射后 2个月 ,经HE染色显示 ,MTEC1细胞在嵌合体小鼠胸腺被膜下皮质区成簇存在 ,体外免疫学试验发现 ,嵌合体小鼠脾细胞含有抗原特异性H-2^d识别限制的杀伤T细胞 (CTL) ,IL -2产生T细胞及增殖应答T细胞 .在MLR试验中 ,嵌合体小鼠脾细胞显示对H-2^d 同种异型抗原的明显耐受 .从而证明MTEC1髓质上皮细胞能在胸腺微环境内诱导H-2^d识别限制的对特异抗原应答的T细胞发育及功能成熟 .由此提出在胸腺髓质区进行“2次胸腺选择”的假说 ,并讨论了其意义 .     

携带HCV核心蛋白原核表达质粒与真核表达质粒的减毒伤寒沙门菌诱导小鼠免疫应答之比较

丙型肝炎病毒（HCV）核心蛋白是丙肝疫苗的重要候选抗原,然而,该蛋白因具有免疫调控作用而影响免疫应答的诱导。构建了HCV核心蛋白的两种表达质粒,一种是体内激活型原核表达质粒pZW-C,另一种是真核表达质粒pCI-C。将该两种质粒转化减毒鼠伤寒沙门菌SL7207,得到重组菌SL7207/pZW-C和SL7207/pCI-C,分别将重组菌口服接种小鼠,检测小鼠的免疫应答,结果发现：① SL7207/pCI-C免疫鼠的CD3⁺CD4⁺ T细胞持续降低,而SL7207/pZW-C免疫鼠的CD3⁺CD4⁺ T细胞无明显改变;② SL7207/pCI-C免疫只诱导低水平抗HCV核心蛋白抗体,加强免疫对抗体阳转率及抗体水平无明显影响,而SL7207/pZW-C免疫组所有小鼠均产生较高水平的抗核心蛋白抗体。③ SL7207/pCI-C免疫鼠脾细胞的体外增殖活性、细胞毒性T细胞活性以及加强免疫对细胞免疫应答的增强作用均明显不及SL7207/pZW-C免疫鼠。结果提示：携带真核表达质粒pCI-C的沙门菌因在小鼠细胞内表达天然形式（结构以及磷酸化修饰）的HCV核心蛋白,可能通过对T细胞的免疫抑制作用而弱化免疫应答。而以携带原核表达质粒pZW-C的沙门菌免疫可避免这一问题,并具有接种方便,成本低廉等优点,从而可望作为基于HCV核心蛋白为靶抗原的HCV疫苗的候选免疫方式。     

戊肝病毒Th表位肽免疫可增强其载体蛋白的体液免疫应答

戊型肝炎病毒衣壳蛋白内包含一个强H-2^d限制性Th表位P34。以该表位肽免疫BALB/c鼠,其脾细胞能够在体外识别重组戊型肝炎病毒衣壳蛋白,剔除实验表明应答细胞几乎完全是CD4⁺ T细胞,证明P34表位肽能有效诱导产生特异性Th细胞。以P34肽初免小鼠,再以包含该表位的重组戊型肝炎病毒抗原（E2）免疫,结果表明,10μg、 20μg E2免疫组在免疫后第1周即有部分小鼠产生抗体,到第3周所有小鼠均能够产生抗体;而对照肽P18初免的小鼠,以20μg E2加强免疫亦无法诱导小鼠产生抗体。这表明,Th表位肽P34初免诱导产生的Th细胞能够有效促进小鼠对携带该表位的载体蛋白的体液免疫应答。     

柯萨奇病毒A组16型灭活抗原对小鼠免疫保护作用的研究

为了研究柯萨奇病毒A组16型(Coxsackievirus A16,CVA16)灭活抗原在小鼠体内所产生免疫保护作用效果,我们选用CVA16临床分离株521-01T,在Vero细胞中进行大量培养,并对培养产物进行甲醛灭活及超速离心纯化。SDS-PAGE和Western blot对纯化的灭活病毒纯度及性质进行初步分析。Al(OH)3+CVA16及单独CVA16抗原,分别经皮下注射免疫雌性ICR小鼠;相同免疫途径、剂量于第14和28d加强免疫2次。ELISA法检测CVA16特异性血清IgG抗体滴度;微量中和试验法鉴定血清中和抗体滴度;酶联免疫斑点试验(ELISPOT)检测特异性T淋巴细胞的活化。对Al(OH)3+CVA16抗原免疫组母鼠所产仔鼠进行脑腔攻毒,检测母传抗体对新生乳鼠的保护作用。结果显示,Al(OH)3+CVA16灭活抗原在小鼠体内能诱生高滴度的特异性抗体,3次免疫后产生的特异性血清IgG抗体滴度最高可达1∶1×105(P=0.000),中和滴度高于1∶256。同时,该抗原还可以诱导特异性T淋巴细胞的活化。以1 000LD50的病毒量脑腔接种48h内新生乳鼠的病毒攻击实验显示,该母传抗体对新生乳鼠具有100%的保护。这一结果表明该灭活CVA16病毒抗原具有较好的免疫原性及保护性,为CVA16灭活疫苗的研究及评价体系提供了参考。     

以恒河猴为模型的DNA疫苗的免疫保护作用研究

研究了以霍乱毒素B亚基（CTB）为载体的重组疟疾多价抗原（AWTE）表位的DNA疫苗在恒河猴中的免疫原性及对相应疟原虫感染的免疫保护作用。结果表明DNA疫苗组免疫2次后即产生了较高水平的细胞免疫和体液免疫,免疫后91天用1.25×10     

性疟原虫DNA疫苗免疫效果的评估

以霍乱毒素Ｂ亚基（ＣＴＢ）为载体,由其基因构建了含有不同时期不同抗原表位的恶性疟原虫的融合基因ＣＴＢ～ＡＷＴＥ、ＣＴＢ～ＮＡＮＰ,前者除含有恶性疟原虫裂殖子表面主要抗原表位杂合多肽基因ＳＰｆ６６外,还含有很强的Ｔ辅助细胞表位ＣＳＴ３和Ｔｃ细胞表位,后者含有子孢子期的Ｂ、Ｔｈ细胞表位。将纯化的质粒免疫Ｂａｌｂ／ｃ纯系小鼠,３次免疫后诱导机体产生了体液免疫和细胞免疫,免疫的小鼠进行疟原虫子孢子攻击实验,保护率为６０％一８０％。将纯化的质粒混合后免疫恒河猴,３次免疫后诱导机体产生了体液免疫和细胞免疫,免疫的恒河猴进行食蟹疟原虫攻击实验,显示了一定的保护作用。     

Immunization with Cholera Toxin B Subunit Induces High-Level Protection in the Suckling Mouse Model of Cholera

Cholera toxin (CT) is the primary virulence factor responsible for severe cholera. Vibrio cholerae strains unable to produce CT show severe attenuation of virulence in animals and humans. The pentameric B subunit of CT (CTB) contains the immunodominant epitopes recognized by antibodies that neutralize CT. Although CTB is a potent immunogen and a promising protective vaccine antigen in animal models, immunization of humans with detoxified CT failed to protect against cholera. We recently demonstrated however that pups reared from mice immunized intraperitoneally (IP) with 3 doses of recombinant CTB were well protected against a highly lethal challenge dose of V. cholerae N16961. The present study investigated how the route and number of immunizations with CTB could influence protective efficacy in the suckling mouse model of cholera. To this end female mice were immunized with CTB intranasally (IN), IP, and subcutaneously (SC). Serum and fecal extracts were analyzed for anti-CTB antibodies by quantitative ELISA, and pups born to immunized mothers were challenged orogastrically with a lethal dose of V. cholerae. Pups from all immunized groups were highly protected from death by 48 hours (64–100% survival). Cox regression showed that percent body weight loss at 24 hours predicted death by 48 hours, but we were unable to validate a specific amount of weight loss as a surrogate marker for protection. Although CTB was highly protective in all regimens, three parenteral immunizations showed trends toward higher survival and less weight loss at 24 hours post infection. These results demonstrate that immunization with CTB by any of several routes and dosing regimens can provide protection against live V. cholerae challenge in the suckling mouse model of cholera. Our data extend the results of previous studies and provide additional support for the inclusion of CTB in the development of a subunit vaccine against V. cholerae.     

Haemobartonellosis in squirrel monkeys (Saimiri sciureus): antagonism between Haemobartonella sp. and experimental Plasmodium falciparum malaria

A hemotropic parasite of the genus Haemo bartonella (rickettsial parasite of the Family Anaplasmataceae) is responsible for latent asymptomatic infection in colony-born Saimiri monkeys. Indeed, many of these animals develop a patent Haemobartonella infection following splenectomy. Such patent parasitism is characterized by an intense Haemobartonella parasitemia which peaks between days 12 and 14 after removal of the spleen and then decreases to become undetectable between days 25 and 30. During the resolving phase of parasitemia, a moderate anemia associated with monocytosis and erythrophagocytosis is observed. In certain Saimiri monkeys, Haemobartonella parasitemia remains latent following removal of the spleen. This indicates that the spleen plays a role but is not necessary to maintain latent Haemobartonella parasitism. It also suggests the existence of heterogeneity in the host immune reactivity to the parasite. Latent or patent haemobartonellosis might raise a problem when Saimiri monkeys are used as experimental hosts of Plasmodium falciparum asexual blood stages, as already noticed with "rodent malaria." Thus we investigated the relationship between Haemobartonella and P. falci parum in splenectomized monkeys. When animals harboring latent Haemobartonella sp. were infected with P. falciparum, the former remained latent and exerted no influence on the course of the P. falciparum parasitemia. In constrast, when P. falciparum was initiated in animals which were in the process of developing patent haemobarto nellosis, the course of the former was protracted and either the animal resisted longer, or it self-cleared the P. falciparum infection. Conversely, patent haemobartonellosis was delayed when splenectomy was performed at different times after initiation of P. falciparum infection in intact monkeys. Our results do not allow us to draw conclusions as to the mechanism(s) of the antagonism between the two parasites, but they emphasize the need to monitor the presence of Haemobartonella when splenectomized Saimiri monkeys are used as experimentals hosts for P. falciparum parasitism.     

Chloroplast‐derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery

Cholera and malaria are major diseases causing high mortality. The only licensed cholera vaccine is expensive; immunity is lost in children within 3 years and adults are not fully protected. No vaccine is yet available for malaria. Therefore, in this study, the cholera toxin‐B subunit (CTB) of Vibrio cholerae fused to malarial vaccine antigens apical membrane antigen‐1 (AMA1) and merozoite surface protein‐1 (MSP1) was expressed in lettuce and tobacco chloroplasts. Southern blot analysis confirmed homoplasmy and stable integration of transgenes. CTB‐AMA1 and CTB‐MSP1 fusion proteins accumulated up to 13.17% and 10.11% (total soluble protein, TSP) in tobacco and up to 7.3% and 6.1% (TSP) in lettuce, respectively. Nine groups of mice (n = 10/group) were immunized subcutaneously (SQV) or orally (ORV) with purified antigens or transplastomic tobacco leaves. Significant levels of antigen‐specific antibody titres of immunized mice completely inhibited proliferation of the malarial parasite and cross‐reacted with the native parasite proteins in immunoblots and immunofluorescence studies. Protection against cholera toxin challenge in both ORV (100%) and SQV (89%) mice correlated with CTB‐specific titres of intestinal, serum IgA and IgG1 in ORV and only IgG1 in SQV mice, but no other immunoglobulin. Increasing numbers of interleukin‐10⁺ T cell but not Foxp3⁺ regulatory T cells, suppression of interferon‐γ and absence of interleukin‐17 were observed in protected mice, suggesting that immunity is conferred via the Tr1/Th2 immune response. Dual immunity against two major infectious diseases provided by chloroplast‐derived vaccine antigens for long‐term (>300 days, 50% of mouse life span) offers a realistic platform for low cost vaccines and insight into mucosal and systemic immunity.     

Assessment of Carrot Callus as Biofactories of an Atherosclerosis Oral Vaccine Prototype

Atherosclerosis is a pathology leading to cardiovascular diseases with high epidemiologic impact; thus, new therapies are required to fight this global health issue. Immunotherapy is a feasible approach to treat atherosclerosis and given that genetically engineered plants are attractive hosts for vaccine development; we previously proved that the plant cell is able to synthesize a chimeric protein called CTB:p210:CETPe, which is composed of the cholera toxin B subunit (CTB) as immunogenic carrier and target epitopes from the cholesteryl ester transfer protein (CETP_461–476) and apolipoprotein B100 (p210). Since CTB:p210:CETPe was expressed in tobacco at sufficient levels to evoke humoral responses in mice, its expression in carrot was explored in the present study looking to develop a vaccine in a safe host amenable for oral delivery; avoiding the purification requirement. Carrot cell lines expressing CTB:p210:CETPe were developed, showing accumulation levels up to 6.1 µg/g dry weight. An immunoblot analysis revealed that the carrot-made protein is antigenic and an oral mice immunization scheme led to evidence on the immunogenic activity of this protein; revealing its capability of inducing serum IgG responses against p210 and CETP epitopes. This study represents a step forward in the development of an attractive oral low-cost vaccine to treat atherosclerosis.     

疟疾多抗原表位基因表达载体的构建及其在烟草中的表达

本文首次报道疟疾多表位抗原基因在转基因烟草中表达成功。疟疾是当今最需要研究有效疫苗的主要传染病之一。过去的研究表明,ＡＷＴＥ基因编码的疟疾多种抗原表位是有效的抗疟表位,ＣＴＢ基因编码的霍乱毒素Ｂ亚基,是一种既能引起细胞免疫又能引起体液免疫的免疫载体和佐剂。本研究把ＡＷＴＥ－ＣＴＢ融合基因构建到植物表达载体ｐＢＶＧ－ｎｙ１上,采用共转化的方法,通过基因枪导入转化烟草。经ＰＣＲ扩增ＡＷＴＥ－ＣＴＢ基因片段检测,证实了疟疾多表位抗原基因在转基因烟草中的整合。ＳＤＳ－ＰＡＧＥ蛋白电泳结果显示转基因烟草中表达了ＡＷＴＥ－ＣＴＢ融合基因分子量相同的特异蛋白。经抗原性分析实验和Ｗｅｓｔｅｒｎ免疫印迹实验结果表明,特异表达的融合蛋白可与ＣＴＢ和ＡＷＴＥ抗体结合,具有ＣＴＢ和ＡＷＴＥ抗原性。     

人工哺育期腹泻婴猴奇异变形杆菌的分离与鉴定

目的对一株人工哺育期引发恒河猴婴猴腹泻的奇异变形杆菌进行了鉴定,为实验猕猴疾病检测、鉴别诊断提供参考依据。方法通过培养特性、菌落形态、染色、生化试验和血清学诊断鉴别等检查,对分离菌株进行初步鉴定,同时,对分离菌株进行致病性试验及药敏试验。结果通过表型生物学特性鉴定,并结合血清学诊断鉴别方法,确证该分离菌株为奇异变形杆菌,应用药敏试验筛选出了高度敏感的抗菌药,控制了该病的继续发生,致病性试验证明,该分离菌株对小白鼠有高致病性。结论分离到的奇异变形杆菌是导致本次婴猴腹泻死亡的病原菌,该菌为条件致病菌,对实验猕猴和研究人员均有潜在的危害,尽管该菌不是国家标准要求排除的病原菌,但该菌引发的传染病将对动物实验造成严重影响,故应引起高度重视。     

Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin

The use of the nontoxic B subunit of cholera toxin (CTB) as mucosal adjuvant and carrier-delivery system for inducing secretory Ab responses has been documented previously with different soluble Ags. In this study, we have evaluated this approach for inducing CTL responses against a prototype Ag, OVA, in the female genital mucosa. We report here the ability of an immunogen comprised of CTB conjugated to OVA (CTB-OVA) given by intravaginal (ivag) route to induce genital OVA-specific CTLs in mice. Using adoptive transfer models, we demonstrate that ivag application of CTB-OVA activates OVA-specific IFN-gamma-producing CD4 and CD8 T cells in draining lymph nodes (DLN). Moreover, ivag CTB induces an expansion of IFN-gamma-secreting CD8+ T cells in DLN and genital mucosa and promotes Ab responses to OVA. In contrast, ivag administration of OVA alone or coadministered with CTB failed to induce such responses. Importantly, we demonstrate that ivag CTB-OVA generates OVA-specific CTLs in DLN and the genital mucosa. Furthermore, genital CD11b+ CD11c+ dendritic cells (DCs), but not CD8+ CD11c+ or CD11c- APCs, present MHC class I epitopes acquired after ivag CTB-OVA, suggesting a critical role of this DC subset in the priming of genital CTLs. Inhibition studies indicate that the presentation of OVA MHC class I epitopes by DCs conditioned with CTB-OVA involves a proteasome-dependent and chloroquine-sensitive mechanism. These results demonstrate that CTB is an efficient adjuvant-delivery system for DC-mediated induction of genital CTL responses and may have implications for the design of vaccines against sexually transmitted infections.